In the past two decades the world has witnessed several devastating coronavirus outbreaks including SARS-CoV in 2002, MERS-CoV in 2012, and the SARS-CoV-2 in 2019 that has caused the COVID-19 pandemic.SARS-CoV-2 likely emerged from bats, evolving into a new harmful strain that is highly fit for human transmission.In the first four-plus months since its initial identification, over 4,700 SARS-CoV-2 variants have been isolated,including diverse mutants that can contribute to high variability in viral pathogenicity. Developing vaccines forSARS-CoV-2 is a valid and ultimate goal that is being actively pursued, yet there are well-founded cautions thatconventional vaccine development will take years and is less straightforward than hoped. Further, the globalprevalence of COVID-19 in more than 200 countries and territories, compounded with the real probability of newrecombination events, will expedite the emergence of novel fit variants that may circumvent any conventionalvaccines or therapeutics currently being evaluated. However, the biomedical field is utterly unprepared for suchscenarios where the conventional vaccines and therapeutics cannot protect us from current or novel virulentSARS-CoV-2 variants.This proposal aims to discover broad-spectrum, cross-neutralizing bispecific antibodies simultaneously targetingnot only SARS-CoV-2 but also two other detrimental coronavirus strains (SARS-CoV and MERS-CoV), in partusing a cutting-edge high throughput functional discovery technology. Such bispecific antibodies can target twocritical spots of a coronavirus, thereby offering an effective measure to tackle large viral variability and potentialtherapeutic resistance. The main objectives of this Phase I study are to discover broad-spectrum bispecificantibody candidates against the three coronaviruses concurrently (Aims 1 and 2) and to optimize these candidatemolecules to obtain final two leads that are feasible for translational research and clinical development. ThisPhase I feasibility study will offer optimized bispecific lead molecules that can be licensed to or co-developed bypharmaceutical companies to facilitate subsequent development as a highly effective therapy and/or passivevaccine against common SARS-CoV-2 and relevant arising mutant strains, thereby making an immediate andsignificant impact on the society and economy. Project Narrative
Several coronavirus outbreaks have been a great threat to global health and economy, in
particular the recent SARS-CoV-2 that has caused the detrimental COVID-19 pandemic.
Unfortunately, there are still no approved therapies or vaccines for this devastating disease. This
proposal aims to discover broad-spectrum, cross-neutralizing bispecific antibody molecules using
a high throughput functional screening approach, which can be used as a therapy and/or vaccine
against multiple coronavirus strains including SARS-CoV-2. Monoclonal Antibodies ; Clinical Treatment Moab ; mAbs ; Biological Assay ; Assay ; Bioassay ; Biologic Assays ; Blood Cells ; Peripheral Blood Cell ; Blood donor ; Cells ; Cell Body ; Chiroptera ; Bats ; Cessation of life ; Death ; Disease ; Disorder ; Disease Outbreaks ; Outbreaks ; Feasibility Studies ; Goals ; Healthcare Systems ; Health Care Systems ; Human ; Modern Man ; Lead ; Pb element ; heavy metal Pb ; heavy metal lead ; Libraries ; Methods ; Mus ; Mice ; Mice Mammals ; Murine ; Probability ; Proteins ; Reagent ; Genetic Recombination ; DNA Recombination ; Recombination ; research and development ; Development and Research ; R & D ; R&D ; Societies ; Technology ; United States ; Vaccines ; Virus ; Work ; Measures ; base ; Phase ; Variant ; Variation ; Coronavirus ; Coronaviridae ; corona virus ; Bispecific Antibodies ; Bi-specific antibodies ; Bifunctional Antibodies ; bsAb ; Evaluation ; Therapeutic ; Spottings ; Event ; System ; Country ; Viral ; mutant ; develop a vaccine ; development of a vaccine ; vaccine formulation ; vaccine development ; novel ; cross reactivity ; Pathogenicity ; SARS Virus ; SARS corona virus ; SARS-Associated Coronavirus ; SARS-CoV ; SARS-Related Coronavirus ; Severe Acute Respiratory Syndrome Virus ; Severe Acute Respiratory Syndrome corona virus ; Severe Acute Respiratory Syndrome coronavirus ; severe acute respiratory syndrome-CoV ; SARS coronavirus ; Pharmaceutical Agent ; Pharmaceuticals ; Pharmacological Substance ; Pharmacologic Substance ; µfluidic ; Microfluidics ; global health ; Affinity ; Recombinants ; Small Business Innovation Research Grant ; SBIR ; Small Business Innovation Research ; Translational Research ; Translational Science ; translation research ; Virulent ; transmission process ; Transmission ; Development ; developmental ; therapy resistant ; resistance to therapy ; resistant to therapy ; therapeutic resistance ; treatment resistance ; next generation ; Prevalence ; innovation ; innovate ; innovative ; therapeutic development ; therapeutic agent development ; effective therapy ; effective treatment ; phase 1 study ; Phase I Study ; screening ; Middle East Respiratory Syndrome Coronavirus ; MERS corona virus ; MERS coronavirus ; MERS virus ; MERS-CoV ; Middle East Respiratory Syndrome Corona Virus ; Middle East Respiratory Syndrome Virus ; Middle East Respiratory Syndrome-CoV ; Middle Eastern Respiratory Syndrome Corona virus ; Middle Eastern Respiratory Syndrome Coronavirus ; Middle Eastern Respiratory Syndrome Virus ; Middle Eastern Respiratory Syndrome-CoV ; Preventive vaccine ; Preventative vaccine ; Prophylactic vaccine ; clinical development ; Immunize ; COVID-19 ; COVID19 ; CV-19 ; CV19 ; corona virus disease 2019 ; coronavirus disease 2019 ; 2019-nCoV ; 2019 novel corona virus ; 2019 novel coronavirus ; COVID-19 virus ; COVID19 virus ; CoV-2 ; CoV2 ; SARS corona virus 2 ; SARS-CoV-2 ; SARS-CoV2 ; SARS-associated corona virus 2 ; SARS-associated coronavirus 2 ; SARS-coronavirus-2 ; SARS-related corona virus 2 ; SARS-related coronavirus 2 ; SARSCoV2 ; Severe Acute Respiratory Distress Syndrome CoV 2 ; Severe Acute Respiratory Distress Syndrome Corona Virus 2 ; Severe Acute Respiratory Distress Syndrome Coronavirus 2 ; Severe Acute Respiratory Syndrome CoV 2 ; Severe Acute Respiratory Syndrome-associated coronavirus 2 ; Severe Acute Respiratory Syndrome-related coronavirus 2 ; Severe acute respiratory syndrome associated corona virus 2 ; Severe acute respiratory syndrome corona virus 2 ; Severe acute respiratory syndrome coronavirus 2 ; Severe acute respiratory syndrome related corona virus 2 ; Wuhan coronavirus ; coronavirus disease 2019 virus ; hCoV19 ; nCoV2 ; COVID-19 vaccine ; 2019-nCoV vaccine ; COVID19 vaccine ; SARS-CoV-2 vaccine ; SARS-CoV2 vaccine ; SARS-coronavirus-2 vaccine ; Severe Acute Respiratory Syndrome CoV 2 vaccine ; Severe acute respiratory syndrome coronavirus 2 vaccine ; corona virus disease 2019 vaccine ; coronavirus disease 2019 vaccine ; vaccine against 2019-nCov ; vaccine against SARS-CoV-2 ; vaccine against SARS-CoV2 ; vaccine against SARS-coronavirus-2 ; vaccine against Severe Acute Respiratory Syndrome CoV 2 ; vaccine against Severe acute respiratory syndrome coronavirus 2 ; vaccine for novel coronavirus ; COVID-19 pandemic ; COVID crisis ; COVID epidemic ; COVID pandemic ; COVID-19 crisis ; COVID-19 epidemic ; COVID-19 global health crisis ; COVID-19 global pandemic ; COVID-19 health crisis ; COVID-19 public health crisis ; COVID19 crisis ; COVID19 epidemic ; COVID19 global health crisis ; COVID19 global pandemic ; COVID19 health crisis ; COVID19 pandemic ; COVID19 public health crisis ; SARS-CoV-2 epidemic ; SARS-CoV-2 global health crisis ; SARS-CoV-2 global pandemic ; SARS-CoV-2 pandemic ; SARS-CoV2 epidemic ; SARS-CoV2 pandemic ; SARS-coronavirus-2 epidemic ; SARS-coronavirus-2 pandemic ; Severe Acute Respiratory Syndrome CoV 2 epidemic ; Severe Acute Respiratory Syndrome CoV 2 pandemic ; Severe acute respiratory syndrome coronavirus 2 epidemic ; Severe acute respiratory syndrome coronavirus 2 pandemic ; corona virus disease 2019 epidemic ; corona virus disease 2019 pandemic ; coronavirus disease 2019 crisis ; coronavirus disease 2019 epidemic ; coronavirus disease 2019 global health crisis ; coronavirus disease 2019 global pandemic ; coronavirus disease 2019 health crisis ; coronavirus disease 2019 pandemic ; coronavirus disease 2019 public health crisis ; coronavirus disease crisis ; coronavirus disease epidemic ; coronavirus disease pandemic ; severe acute respiratory syndrome coronavirus 2 global health crisis ; severe acute respiratory syndrome coronavirus 2 global pandemic ; COVID-19 patient ; COVID infected patient ; COVID patient ; COVID positive patient ; COVID-19 infected patient ; COVID-19 positive patient ; COVID19 patient ; COVID19 positive patient ; SARS-CoV-2 infected patient ; SARS-CoV-2 patient ; SARS-CoV-2 positive patient ; coronavirus disease 2019 infected patient ; coronavirus disease 2019 patient ; coronavirus disease 2019 positive patient ; coronavirus disease infected patient ; coronavirus disease patient ; coronavirus disease positive patient ; coronavirus patient ; patient infected with COVID ; patient infected with COVID-19 ; patient infected with SARS-CoV-2 ; patient infected with coronavirus disease ; patient infected with coronavirus disease 2019 ; patient infected with severe acute respiratory syndrome coronavirus 2 ; patient with COVID ; patient with COVID-19 ; patient with COVID19 ; patient with SARS-CoV-2 ; patient with coronavirus disease ; patient with coronavirus disease 2019 ; patient with severe acute respiratory distress syndrome coronavirus 2 ; severe acute respiratory syndrome coronavirus 2 infected patient ; severe acute respiratory syndrome coronavirus 2 patient ; severe acute respiratory syndrome coronavirus 2 positive patient ; SARS-CoV-2 antibody ; COVID-19 antibody ; SARS-CoV2 antibody ; antibody against COVID-19 ; antibody against SARS-CoV-2 ; antibody against SARS-CoV2 ; antibody against coronavirus disease 2019 ; antibody against severe acute respiratory syndrome coronavirus 2 ; antibody to COVID-19 ; antibody to SARS-CoV-2 ; antibody to SARS-CoV2 ; antibody to coronavirus disease 2019 ; antibody to severe acute respiratory syndrome coronavirus 2 ; coronavirus disease 2019 antibody ; severe acute respiratory syndrome coronavirus 2 antibody ; SARS-CoV-2 variant ; 2019-nCoV variant ; 2019-nCoV variant forms ; 2019-nCoV variant strains ; COVID-19 variant ; COVID-19 variant forms ; COVID-19 variant strains ; SARS-CoV-2 variant forms ; SARS-CoV-2 variant strains ; coronavirus disease 2019 variant ; coronavirus disease 2019 variant forms ; coronavirus disease 2019 variant strains ; severe acute respiratory syndrome coronavirus 2 variant ; severe acute respiratory syndrome coronavirus 2 variant forms ; severe acute respiratory syndrome coronavirus 2 variant strains ;
